{"id":273521,"date":"2020-10-30T06:25:58","date_gmt":"2020-10-30T10:25:58","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=273521"},"modified":"2020-10-30T06:25:58","modified_gmt":"2020-10-30T10:25:58","slug":"ph-govt-to-meet-astrazeneca-for-possible-vaccine-vs-covid-19","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/10\/30\/ph-govt-to-meet-astrazeneca-for-possible-vaccine-vs-covid-19\/","title":{"rendered":"PH gov&#8217;t to meet AstraZeneca for possible vaccine vs. Covid-19"},"content":{"rendered":"<figure id=\"attachment_262725\" aria-describedby=\"caption-attachment-262725\" style=\"width: 1280px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-262725\" src=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280.jpg\" alt=\"\" width=\"1280\" height=\"768\" srcset=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280.jpg 1280w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280-300x180.jpg 300w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280-768x461.jpg 768w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/07\/syringe-1884758_1280-1024x614.jpg 1024w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/a><figcaption id=\"caption-attachment-262725\" class=\"wp-caption-text\">The clinical trials of AstraZeneca and University of Oxford&#8217;s experimental Covid-19 vaccine have recently resumed in the US after it was put on hold due to an illness of a volunteer. (Pixabay photo)<\/figcaption><\/figure>\n<p><strong>MANILA<\/strong>\u00a0\u2013 Foreign Affairs Secretary Teodoro Locsin Jr. said officials from the Philippine government are scheduled to meet on Friday with representatives from AstraZeneca, one of the leading developers of a candidate vaccine against coronavirus disease (Covid-19).<\/p>\n<p>&#8220;We&#8217;re meeting AstraZeneca later with FDA (Food and Drug Administration). Will assure them fairness across the board, no favors, no funny stuff, we need all the vaccines we can get,&#8221; he said in a tweet.<\/p>\n<p>Locsin noted that once the supply is available, the European drug maker&#8217;s candidate vaccine would be &#8220;sold at cost&#8221;.<\/p>\n<p>Meanwhile, he clarified that AstraZeneca has no plans to extend its trials to Southeast Asia after FDA Director-General Eric Domingo said the pharmaceutical firm has expressed interest to conduct a clinical study in the Philippines.<\/p>\n<p>&#8220;I just talked to AstraZeneca. It is not conducting trials anywhere in Southeast Asia and yet Indonesia has preordered 100 million doses; so since we are all equal members of one human race it doesn&#8217;t matter. The primary consideration should be cost per dosage,&#8221; he said.<\/p>\n<p>The clinical trials of AstraZeneca and University of Oxford&#8217;s experimental Covid-19 vaccine have recently resumed in the US after it was put on hold due to an illness of a volunteer.<\/p>\n<p>Manila is also in talks with Chinese firms currently in the final stages of clinical trials.<\/p>\n<p>Last week, China\u2019s Sinovac Biotech submitted to the FDA Philippines its application to conduct Phase 3 of clinical trials of its vaccine in the country.<\/p>\n<p>The government is also evaluating vaccines of Russia\u2019s Gamaleya Research Institute and other pharmaceutical companies, including Pfizer.<\/p>\n<p>The Department of Health earlier said the third phase of the World Health Organization (WHO) Solidarity Trial on a possible Covid-19 vaccine is also set to start in the Philippines by end of 2020.<\/p>\n<p>Manila, meanwhile, has secured membership to the Gavi COVAX alliance to ensure access to the global Covid-19 vaccine supply.<\/p>\n<p>The COVAX or Covid-19 Vaccines Global Access Facility, co-led by the WHO, represents the largest portfolio of potential Covid-19 vaccines. It is a global initiative among vaccine manufacturers and foreign governments to provide countries an efficient vaccine against coronavirus.<\/p>\n<p>The full list of candidate vaccines under COVAX is as follows:<\/p>\n<ul>\n<li>Inovio, United States of America (Phase I\/II)<\/li>\n<li>Moderna, United States of America (Phase III)<\/li>\n<li>CureVac, Germany (Phase I)<\/li>\n<li>Institut Pasteur\/Merck\/Themis, France\/ United States of America \/Austria (Preclinical)<\/li>\n<li>AstraZeneca\/University of Oxford, United Kingdom of Great Britain and Northern Ireland (Phase III)<\/li>\n<li>University of Hong Kong, China (Preclinical)<\/li>\n<li>Novavax, United States of America (Phase I\/II)<\/li>\n<li>Clover Biopharmaceuticals, China (Phase I)<\/li>\n<li>University of Queensland\/CSL, Australia (Phase I)<\/li>\n<\/ul>\n<p>As of October 29, there are 376,935 confirmed Covid-19 cases in the country, including 7,147 deaths and 329,848 recoveries.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MANILA\u00a0\u2013 Foreign Affairs Secretary Teodoro Locsin Jr. said officials from the Philippine government are scheduled to meet on Friday with &hellip;<\/p>\n","protected":false},"author":44,"featured_media":262725,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,95],"tags":[],"class_list":["post-273521","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-news-ph","mauthors-joyce-ann-l-rocamora","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/273521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=273521"}],"version-history":[{"count":2,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/273521\/revisions"}],"predecessor-version":[{"id":273523,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/273521\/revisions\/273523"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/262725"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=273521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=273521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=273521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}